Get the Stockscreener App
5.28
1.86%
-0.10
Ardelyx Inc stock is traded at $5.28, with a volume of 2.34M.
It is down -1.86% in the last 24 hours and down -5.88% over the past month.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
See More
Previous Close:
$5.38
Open:
$5.38
24h Volume:
2.34M
Relative Volume:
0.59
Market Cap:
$1.30B
Revenue:
$427.68M
Net Income/Loss:
$-58.06M
P/E Ratio:
-22.17
EPS:
-0.2382
Net Cash Flow:
$-37.50M
1W Performance:
+0.19%
1M Performance:
-5.88%
6M Performance:
-31.78%
1Y Performance:
+12.34%
1-Day Range:
$5.19
$5.39
1-Week Range:
$5.15
$5.56
52-Week Range:
$4.075
$8.40
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
5.28 | 1.30B | 427.68M | -58.06M | -37.50M | -0.2382 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-03-25 | Resumed | Raymond James | Strong Buy |
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| May-02-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-07-25 | Resumed | Ladenburg Thalmann | Buy |
| Mar-04-25 | Initiated | BTIG Research | Buy |
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
Lobbying Update: $20,000 of ARDELYX INC lobbying was just disclosed - Quiver Quantitative
ARDX Edges Up After Hours On IBSRELA Momentum And Profitability ‘Right Around The Corner’ - Stocktwits
ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug - Stocktwits
Ardelyx (NASDAQ: ARDX) draws $50M Term F loan maturing in 2030 - Stock Titan
Ardelyx: The Market Is Right To Discount This Revenue Growth - Seeking Alpha
Price to book forward of Ardelyx, Inc. – NASDAQ:ARDX - TradingView
Price to sales forward of Ardelyx, Inc. – NASDAQ:ARDX - TradingView
Price to earnings forward of Ardelyx, Inc. – TRADEGATE:41X - TradingView
Ardelyx, Inc.'s (NASDAQ:ARDX) Shift From Loss To Profit - 富途牛牛
Ardelyx (ARDX) Faces New Medicare Rules For Xphozah After Court Ruling - simplywall.st
ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? - Stocktwits
Ardelyx stock decline attributed to setback in Xphozah appeal - MSN
ARDX Stock Tumbles As Xphozah Loses Final Medicare Reimbursement Battle - TradingView
Ardelyx (ARDX) Faces Appeal Setback but Maintains Buy Rating - GuruFocus
Jefferies Maintains Ardelyx(ARDX.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Ardelyx falls after setback in Xphozah appeal (ARDX:NASDAQ) - Seeking Alpha
Ardelyx Loses Appeal of HHS Reclassification of Kidney Drug - Bloomberg Law News
Ardelyx Inc (ARDX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ardelyx stock trades down as mixed technical signals cap upside potential - Traders Union
ARDX Forecast — Price Target — Prediction for 2027 - TradingView
Ardelyx, Inc. Actuals & Estimates (NASDAQ:ARDX) - TradingView
Ardelyx, Inc. Actuals & Estimates (FWB:41X) - TradingView
41X Forecast — Price Target — Prediction for 2027 - TradingView
Is Ladenburg’s IBSRELA Focus Quietly Reframing Ardelyx’s (ARDX) Risk‑Reward Story? - simplywall.st
Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last? - Yahoo! Finance Canada
Ardelyx Inc (ARDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ardelyx Stock Up 70%: What to Know About This $490,000 Insider Transaction - The Globe and Mail
What’s Fueling Optimism Around Ardelyx, Inc. (ARDX)’s Sales and Pipeline? - Yahoo Finance
Ardelyx Inc (ARDX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Form 4 Ardelyx Inc For: 22 June By Investing.com - Investing.com Australia
Ardelyx chief patient officer sells $490k in stock By Investing.com - Investing.com Australia
Ardelyx chief patient officer sells $490k in stock - Investing.com
Ardelyx Insider Sold Shares Worth $490,487, According to a Recent SEC Filing - marketscreener.com
Ardelyx (ARDX) Chief Patient Officer sells shares, exercises 31,000 options - Stock Titan
5 Best Low Priced Stocks to Get Rich in 2026 - Insider Monkey
Ardelyx (ARDX) director granted RSUs and 39,715-share stock option - Stock Titan
Laura A. Williams proposes sale of 31,000 shares (ARDX) - Stock Titan
Ardelyx (ARDX) director receives 26,455 RSUs and 39,715-share option - Stock Titan
Equity grants to Ardelyx (ARDX) director under compensation program - Stock Titan
Ardelyx (ARDX) director Cadoret-Manier receives RSU and option grants - Stock Titan
Ardelyx (ARDX) director receives RSUs and stock options as compensation - Stock Titan
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):